We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Induced production of anti-etanercept antibody in collagen-induced arthritis.
- Authors
HYOJU YI; JURYUN KIM; HYERIN JUNG; YERI ALICE RIM; YOUNGKYUN KIM; SEUNG MIN JUNG; SUNG-HWAN PARK; JI HYEON JU
- Abstract
Etanercept is a widespread biological drug for the treatment of rheumatoid arthritis, which inhibits tumor necrosis factor-α (TNF-α). Recently, the presence of antibodies targeting TNF-α inhibitors such as infliximab and adalimumab, was reported. However, few reports have studied etanercept in a mouse model of arthritis. We investigated the induction of anti-etanercept antibody production, along with the antibody's potential interfering effects on the biological function of etanercept, in mice with collagen-induced arthritis (CIA). CIA mice received an intraperitoneal injection of etanercept (25, 100 or 400 μg per mouse). The degree of inflammation and cartilage erosion was evaluated, and the number of osteoclasts in the ankle joints was assessed by TRAP staining. The level of pro-inflammatory cytokines in the serum was measured. To analyze the anti-osteoporotic effect of etanercept, microfocal computed tomography analyses of femurs and tibias were performed. Etanercept treatment decreased both the incidence and severity of arthritis in a dose-dependent manner, except for the highest dose of 400 μg. The mice that were treated with 25 and 100 μg etanercept showed an improvement in inflammation, cartilage damage, and even bone loss. However, mice treated with 400 μg etanercept showed no significant improvement in any of the tested parameters. Using a customized enzyme-linked immunosorbent assay (ELISA), the presence of the anti-etanercept antibody was detected in the serum in this treatment-refractory group. The therapeutic effect of etanercept was reduced in the CIA mice that developed the anti-etanercept antibody. In conclusion, the production of an anti-etanercept antibody can be induced in CIA mice, and this antibody can considerably reduce the anti-arthritic and anti-osteoporotic effects of etanercept.
- Subjects
ETANERCEPT; RHEUMATOID arthritis; TUMOR necrosis factors; INFLIXIMAB; ADALIMUMAB
- Publication
Molecular Medicine Reports, 2014, Vol 9, Issue 6, p2301
- ISSN
1791-2997
- Publication type
Article
- DOI
10.3892/mmr.2014.2127